The Government Calls Telehealth Prescribing Permanent. The Rule Expires in 113 Days.

A rural psychiatrist told the Pew Charitable Trusts a few years ago what it actually looks like when a patient has to choose between an hour’s drive to a clinic and a five-minute video call. “I have a lot of patients who will never want to go back,” she said. “A lot of people don’t have transportation, gas money. We live in a rural area, so it’s hard. I have patients that drive an hour to come and see me, so it’s easier to just put up their camera versus driving an hour [here] and an hour back.” She was describing buprenorphine care over video — the medication that, alongside methadone, is the most effective tool anyone has for keeping a person with opioid use disorder alive and out of withdrawal.

That camera stays on because of a rule that has never once been made permanent. It has been extended, re-extended, and quietly saved from lapsing so many times that “permanent” has become the word federal agencies use for something they keep having to renew.

The government keeps calling this policy durable. The policy itself keeps having an expiration date.

Here’s the sentence you won’t see in the press release: the current DEA extension of telehealth prescribing flexibilities for controlled substances — including buprenorphine, the front-line medication for opioid use disorder — runs out December 31, 2026. Today is September 9. That’s 113 days.

What the rule actually does, in plain terms

Before 2020, if you wanted to start buprenorphine, federal law generally required an in-person exam first. Then COVID-19 hit, DEA and the Substance Abuse and Mental Health Services Administration suspended that requirement under emergency authority, and something unplanned happened: it worked. Patients who couldn’t get to a clinic — because they didn’t have a car, because the nearest prescriber was ninety minutes away, because showing up in person meant explaining to a boss or a parole officer where they’d been — started treatment anyway, on a phone or a laptop, and stayed on it.

As of January 2025, DEA and HHS made that flexibility a standing final rule: patients can get a buprenorphine prescription through an audio-video or audio-only telehealth visit without ever seeing a provider face to face first, and can continue on that basis for up to six months before any in-person requirement kicks in. That is the part getting called “permanent” in the current wave of coverage — Pew’s own January 2026 write-up uses exactly that word, echoed by outlets like the Benton Institute. What actually happened is narrower: DEA extended the broader telemedicine flexibility for all controlled substances — not just buprenorphine — through the end of 2026, and rolled the buprenorphine-specific provisions into that same clock.

If you are on buprenorphine right now because a clinic mailed you a script after a video visit, none of this changes anything for you today. Nothing lapses this month. But the legal basis for that prescription is a rule with a calendar date on it, not a law, and the date is in four months.

We have watched this exact clock run down before

This is not a new kind of anxiety for the field. In the fall of 2023 and again in 2024, providers and patient advocates spent months warning about a “telehealth cliff” — the prior extension was set to expire, Congress and DEA moved at the last possible moment, and clinics spent that stretch triaging which patients to convert to in-person visits in case the flexibility actually died. It didn’t, both times. But “didn’t die yet” is not the same promise as “won’t die,” and the operational cost of that uncertainty — the compliance staff hours, the patient anxiety, the clinics that quietly stopped accepting new telehealth-only patients rather than risk a cliff — is real and recurring.

Go back further and the pattern is older than telehealth. Methadone clinics fought a similar fight for decades: a treatment proven to work, delivered through a delivery mechanism the federal government treated as a temporary accommodation rather than standard care, renewed by administrative grace rather than settled into law. Every renewal cycle is a chance for the flexibility to quietly not get renewed, and every clinic that built its patient panel around the assumption that it would gets to find out the hard way. Bipartisan legislation to make the telehealth flexibility permanent by statute — not by rule — has been reintroduced in the Senate more than once. It has not passed. That is the difference between a policy and a habit: a policy survives the person who liked it. A habit needs someone to keep choosing it, on schedule, every year.

Bipartisan legislation to make the telehealth flexibility permanent by statute — not by rule — has been reintroduced in the Senate more than once.

Why this isn’t just a compliance footnote

If you’re the one on the medication, here’s the part that matters: telehealth access to buprenorphine isn’t a convenience feature, it’s the difference between staying in treatment and falling out of it. CDC’s own analysis of buprenorphine access has repeatedly found that rural counties have a fraction of the prescriber density of urban ones — in some rural counties, the nearest in-person MOUD prescriber is a genuine multi-hour round trip. Every hour of travel is an hour a person has to explain, arrange child care around, take off work for, or simply doesn’t have. Relapse doesn’t wait for a ride to become available. A missed dose because the only prescriber willing to see you is ninety minutes away is not a scheduling inconvenience — it’s a withdrawal risk, and withdrawal risk is overdose risk.

Sarah, a nurse in rural Tennessee, put it more bluntly in an account published by a telehealth MAT provider: “I never thought I could get help without everyone in my small town knowing. Telehealth gave me my privacy and my life back.” That’s not a marketing line dressed up as a policy point — it’s the actual mechanism. In a small town, the parking lot outside the one clinic that prescribes buprenorphine is not anonymous. Everyone who works there, everyone who parks there, everyone who happens to drive past at 9 a.m. on a Tuesday can put together what that building is for. A video call from your own kitchen doesn’t have a parking lot.

That’s also the piece that gets lost when this story gets told only as a Washington process story about rulemaking calendars. The provider quoted above wasn’t describing an abstraction. She was describing patients who, given the option, chose the camera every time — not because it was easier, but because the alternative genuinely wasn’t available to them. Multiply that by every rural county without a second prescriber, every parent who can’t leave a shift, every person for whom “just drive to the clinic” assumes a car, gas money, and a boss who doesn’t ask questions, and the telehealth rule stops looking like an administrative convenience and starts looking like the actual infrastructure of rural addiction medicine.

Arizona is a case study in what’s actually at stake. The state ranks near the bottom nationally for behavioral health access, and fewer than one in twenty Arizonans with opioid use disorder currently receive buprenorphine or methadone — a gap driven in large part by exactly the geography the rural psychiatrist described: county after county with no in-person MOUD prescriber within a reasonable drive. A state that AI-matches patients to nearby facilities through tools like AHCCCS’s new locator is making a bet that “nearby” is a meaningful concept for addiction care. For a lot of rural Arizona, telehealth is the only version of “nearby” that exists. If the federal flexibility lapses, that bet doesn’t just get harder to win — for some patients, “nearby” stops referring to anything real.

What would an actual lapse look like, mechanically, if DEA let the clock run out this time? Prescribers would be barred from starting new patients on buprenorphine through telehealth without a prior in-person exam, and the six-month audio-only continuation window would close for patients already using it. Existing patients wouldn’t lose their medication overnight, but every renewal would suddenly require the in-person visit the whole system was built to route around. Clinics that scaled up telehealth-only panels over the past three years — betting, reasonably, that a rule extended four times in a row would probably be extended a fifth — would be the ones scrambling hardest, because they’d have the most patients with no in-person relationship on file to fall back on.

Existing patients wouldn’t lose their medication overnight, but every renewal would suddenly require the in-person visit the whole system was built to route around.

If you’re on buprenorphine through a telehealth visit right now: nothing about your prescription changes this week, this month, or most likely this year. The six-month audio-only pathway, the ability to start without an in-person visit — all of that is intact through December 31, 2026, and past extensions have a track record of landing at the last minute rather than lapsing outright. That’s not a guarantee. It’s a pattern, and patterns break. What’s stable regardless of what DEA does in December: naloxone remains legal, available, and federally supported everywhere in the country, and 988 doesn’t require a prescription or a video appointment to answer.

The provider-side move that actually matters this week

For clinics and prescribers reading this and thinking “we’ll deal with it in December” — that was the plan in 2023 too, and it turned four months of runway into four weeks of scrambling. The concrete move right now, this week, is an audit: pull the list of every patient currently on a telehealth-only induction or audio-only continuation, and flag which ones have never had an in-person visit with your practice. Those are the patients you’d need to either see in person or transition to a different care pathway if the flexibility lapses on schedule. Knowing that number in September is a staffing plan. Finding it out in late December is a crisis.

There is a version of this story where DEA extends the rule again in November or December, providers breathe out, and the whole cycle resets for another year. There is another version where the extension slips, or Congress finally acts on the permanent legislation, or nothing happens and clinics spend January scrambling exactly like they did two years ago. Nobody currently knows which version we’re in — including, it’s worth saying plainly, DEA itself, which has shown no sign of announcing its intentions before the deadline forces its hand, same as every year before this one.

What’s certain is smaller and more stubborn: the rural psychiatrist’s patients are still going to prefer the camera to the ninety-minute round trip, for exactly the reasons she described, for as long as someone in Washington keeps deciding, one extension at a time, to let them.